Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 10 | 2024 | 189 | 1.670 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2024 | 165 | 1.220 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 274 | 1.140 |
Why?
|
| Living Donors | 5 | 2024 | 64 | 0.920 |
Why?
|
| Hepatectomy | 3 | 2024 | 59 | 0.800 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 301 | 0.470 |
Why?
|
| Patient Selection | 2 | 2015 | 445 | 0.430 |
Why?
|
| Donor Selection | 1 | 2012 | 16 | 0.400 |
Why?
|
| Bile Duct Neoplasms | 1 | 2008 | 41 | 0.310 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 258 | 0.300 |
Why?
|
| Antiviral Agents | 3 | 2024 | 314 | 0.270 |
Why?
|
| Learning Curve | 1 | 2024 | 23 | 0.240 |
Why?
|
| Operative Time | 1 | 2024 | 63 | 0.240 |
Why?
|
| Waiting Lists | 2 | 2018 | 48 | 0.220 |
Why?
|
| Tissue Donors | 2 | 2018 | 132 | 0.210 |
Why?
|
| Postoperative Complications | 2 | 2024 | 1130 | 0.210 |
Why?
|
| Pancreas Transplantation | 1 | 2002 | 21 | 0.210 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 96 | 0.210 |
Why?
|
| Hepatitis C | 1 | 2024 | 139 | 0.210 |
Why?
|
| Celiac Disease | 1 | 2002 | 17 | 0.210 |
Why?
|
| Drainage | 1 | 2002 | 144 | 0.190 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 330 | 0.180 |
Why?
|
| Liver | 3 | 2011 | 785 | 0.180 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 88 | 0.180 |
Why?
|
| Blood Group Incompatibility | 1 | 2018 | 10 | 0.150 |
Why?
|
| Resource Allocation | 1 | 2018 | 20 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 42 | 0.150 |
Why?
|
| Prognosis | 4 | 2024 | 1564 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 607 | 0.140 |
Why?
|
| Minority Groups | 1 | 2018 | 140 | 0.140 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 12 | 0.120 |
Why?
|
| Catheter Ablation | 1 | 2015 | 137 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2024 | 5142 | 0.110 |
Why?
|
| Survival Rate | 3 | 2024 | 787 | 0.100 |
Why?
|
| Humans | 13 | 2024 | 59339 | 0.100 |
Why?
|
| Liver Circulation | 1 | 2011 | 11 | 0.100 |
Why?
|
| Iohexol | 1 | 2011 | 18 | 0.100 |
Why?
|
| Poloxamer | 1 | 2011 | 13 | 0.100 |
Why?
|
| Hepatic Veins | 1 | 2011 | 13 | 0.100 |
Why?
|
| Hepatic Artery | 1 | 2011 | 21 | 0.100 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 55 | 0.100 |
Why?
|
| Portal Vein | 1 | 2011 | 37 | 0.100 |
Why?
|
| Middle Aged | 9 | 2024 | 16246 | 0.090 |
Why?
|
| Transplantation, Homologous | 3 | 2011 | 231 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 643 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2323 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2024 | 5981 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2011 | 245 | 0.080 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2008 | 1 | 0.080 |
Why?
|
| Graft Survival | 1 | 2009 | 279 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2011 | 307 | 0.080 |
Why?
|
| Female | 9 | 2024 | 30835 | 0.080 |
Why?
|
| Ganciclovir | 1 | 2008 | 19 | 0.080 |
Why?
|
| Iron Overload | 1 | 2007 | 4 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 354 | 0.070 |
Why?
|
| Liver Failure | 1 | 2007 | 16 | 0.070 |
Why?
|
| Anastomosis, Surgical | 2 | 2011 | 97 | 0.070 |
Why?
|
| Viral Matrix Proteins | 1 | 2008 | 51 | 0.070 |
Why?
|
| Global Health | 1 | 2008 | 161 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 69 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 88 | 0.070 |
Why?
|
| Male | 8 | 2024 | 27518 | 0.070 |
Why?
|
| Bacteremia | 1 | 2007 | 94 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2008 | 216 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 114 | 0.070 |
Why?
|
| Incidence | 1 | 2008 | 1232 | 0.060 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2024 | 21 | 0.060 |
Why?
|
| Aged | 5 | 2024 | 13300 | 0.060 |
Why?
|
| Tissue and Organ Procurement | 2 | 2018 | 37 | 0.060 |
Why?
|
| Adult | 5 | 2024 | 15741 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2024 | 140 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2021 | 12 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2021 | 10 | 0.050 |
Why?
|
| Time Factors | 4 | 2011 | 3567 | 0.050 |
Why?
|
| Sofosbuvir | 1 | 2021 | 18 | 0.050 |
Why?
|
| Fluorenes | 1 | 2021 | 13 | 0.050 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2021 | 25 | 0.050 |
Why?
|
| Carbamates | 1 | 2021 | 25 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2021 | 140 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2021 | 35 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2021 | 59 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 281 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 123 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2018 | 32 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2018 | 31 | 0.040 |
Why?
|
| Recurrence | 2 | 2009 | 576 | 0.030 |
Why?
|
| United States | 2 | 2024 | 7495 | 0.030 |
Why?
|
| Young Adult | 1 | 2024 | 4321 | 0.030 |
Why?
|
| Phlebography | 1 | 2011 | 43 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2011 | 133 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 220 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 338 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 522 | 0.020 |
Why?
|
| Risk Factors | 2 | 2009 | 4999 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 387 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 450 | 0.020 |
Why?
|
| Viremia | 1 | 2008 | 44 | 0.020 |
Why?
|
| Transplants | 1 | 2007 | 9 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 228 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 228 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2007 | 188 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 672 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1295 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1907 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1448 | 0.010 |
Why?
|
| Veterans | 1 | 2007 | 723 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 19614 | 0.010 |
Why?
|